Introduction
Datamonitor estimates that approximately 115 million individuals suffer from
metabolic syndrome in the seven major markets. This patient population is set to
grow rapidly in response to the rising obesity and diabetes epidemics. Research
conducted by Datamonitor reveals that there is a strong unmet need for clearer
guidance regarding the diagnosis and treatment of metabolic syndrome patients.
Scope of this report
- Determination of the prevalence of metabolic syndrome and its component
conditions
- Evaluation of physician awareness of metabolic syndrome and its
importance, with analysis of physician perceptions of the treatment of the
condition
- Assessment of the potential of existing drug classes and developmental
compounds in the treatment of metabolic syndrome
- Discussion of non-physician stakeholder issues, such as reimbursement and
regulatory issues, drawing on examples from each of the 7 major markets
Research and analysis highlights
The awareness of metabolic syndrome has greatly increased although there
remains an unmet need for clearer and more applicable diagnostic and treatment
guidelines and for a strong public health message to increase public awareness
of the consequences of obesity and sedentary lifestyles.
There is a certain resistance among physicians to use pharmacological therapy
to treat metabolic syndrome. This is fueled by concerns over the effects of
long-term drug administration in asymptomatic patients, by a lack of officially
indicated drugs and by the limited availability of clinical trial data for the
use of drug therapy in this setting.
Key reasons to read this report
- Target physicians more effectively, through an understanding of
prescribing behavior and its influences
- Evaluate the potential of existing and developmental drug classes for the
treatment of metabolic syndrome
- Recognize lucrative target populations, in terms of unmet need and patient
potential, in order to successfully position developmental products
View Cart
